Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17438946 | 0.98 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1MAPTTSHRMEN1 | |
| SCHEMBL16115677 | 0.85 | KDM4E (0.46) | HSP90AA1MAPTTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL17438482 | 0.84 | KDM4E (0.45) | HSP90AA1MAPTTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL17438763 | 0.84 | KDM4E (0.49) | HSP90AA1MAPTTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL17438783 | 0.83 | KDM4E (0.48) | HSP90AA1MAPTTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL1339008 | 0.80 | KDM4E (0.60) | HSP90AA1MAPTTSHRMEN1KMT2A | |
| SCHEMBL554704 | 0.77 | MGLL (0.67) | HSP90AA1HSP90AB1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL15754906 | 0.76 | PHGDH (0.66) | MAPTTSHRKMT2ASMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL9614659 | 0.75 | PHGDH (0.64) | MAPTTSHRKMT2ASMN1; SMN2KDM4E | |
| Nicopholine SCHEMBL967933 | 0.73 | PKM (0.61) | MAPTTSHRMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978427-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR INT AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| EP-2978427-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR INT AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| EP-2978427-A1 | FE(III) COMPLEXES FOR TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANAEMIAS | Vifor (International) AG (CH) | 2016-02-03 | — | — | EP | disclosed |
| US-9248134-B1 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-02-02 | — | — | US | disclosed |
| US-9248134-B1 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-02-02 | — | — | US | disclosed |
| US-9248134-B1 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-02-02 | — | — | US | disclosed |
| US-20160015716-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-01-21 | — | — | US | disclosed |
| US-20160015716-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-01-21 | — | — | US | disclosed |
| US-20160015716-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-01-21 | — | — | US | disclosed |
| WO-2014154797-A1 | FE(III) COMPLEXES FOR TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANAEMIAS | VIFOR (INTERNATIONAL) AG (CH) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015716-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | HSP90AA1 1607/4885HSP90AB1 1626/4885MAPT 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.